ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
51 announcements with these filters
Shelter Pharma cancelled its H2 FY2026 Investor Conference Call scheduled for June 10, 2026. A revised date will be announced later, delaying management's performance update.
Shelter Pharma completed a ₹1.35 Crore export order for Taha Drugs & Chemicals. Dispatch to Sudan has commenced, marking successful contract execution and revenue realization.
Shelter Pharma received a manufacturing license renewal for Ayurvedic products from the Government of Gujarat. The license is valid until September 2030, ensuring uninterrupted operations.
Shelter Pharma reported zero deviation in utilizing ₹25.31 Crore raised via preferential warrant issues. Funds were fully deployed toward working capital requirements as approved.
Shelter Pharma Ltd reported revenue from operations of ₹39.8 Cr (+49.6% YoY) and net profit of ₹4.5 Cr (+21.6% YoY) for H2 FY26.
Shelter Pharma reported a net profit of ₹9.03 Crore for the financial year ended March 31, 2026. The board also appointed CA Ismail Lakhani as internal auditor.
Shelter Pharma scheduled a Board Meeting for May 28, 2026, to approve audited financial results. The meeting covers performance for the half-year and full-year ended March 2026.
Shelter Pharma reports continuous positive customer feedback for its healthcare products across various platforms. This trend strengthens brand credibility and supports long-term growth prospects.
Shelter Pharma will participate in the iPHEX 2026 exhibition at Bharat Mandapam. This strategic move aims to enhance global visibility and explore new export opportunities.
Shelter Pharma successfully conducted a CME program in Patna attended by 32 doctors. The session strengthened product awareness and professional relationships within the medical fraternity.
Shelter Pharma launched FOLIMAN Folic Acid Tablets in international markets on May 11, 2026. This expansion into nutraceuticals aims to strengthen its global healthcare segment presence.
Shelter Pharma Limited has allotted 1,11,000 equity shares at Rs. 42.25 each following the conversion of warrants by a non-promoter investor. The company received Rs. 0.35 Crore as the remaining 75% exercise price. Consequently, the paid-up equity share capital increased to Rs. 16.84 Crore.
Shelter Pharma Ltd received repeat international purchase orders worth USD 84,450 (approx. ₹0.80 Crore) from Taha Drugs & Chemicals Co. Ltd. The order involves supplying D3 Cure and Joemega capsules. This development enhances the company's global footprint and contributes to revenue growth.
Shelter Pharma Limited approved the conversion of 2,79,000 warrants into 1,14,000 equity shares at its Board Meeting on May 01, 2026. The company received ₹0.36 Crore as the remaining 75% exercise price from three non-promoter investors. This conversion increases the company's paid-up equity share capital to ₹16.73 Crore.
Shelter Pharma Limited has received an international purchase order worth USD 103,950 (approx. ₹0.98 Crore) from Taha Drugs & Chemicals Co. Ltd. for 189,000 boxes of 'All Vitamins' tablets. This order marks a significant milestone in the company's global expansion and revenue growth journey.
Shelter Pharma Limited secured an international order worth $1,44,000 (₹1.35 Crore) from Sudan-based Taha Drugs & Chemicals Co. Ltd. The contract involves supplying Joemega Capsules and All Vitamins tablets within two months. This noteworthy export order enhances the company's international footprint in the nutraceutical market.
Shelter Pharma Ltd has commenced product exports to Sudan, including its daily multivitamin 'Allvitamin'. This move is part of the company's regular international supply operations to African markets, aimed at strengthening its global presence and diversifying revenue streams through consistent international supply relationships.
Shelter Pharma Limited has appointed key senior management personnel, including Mr. Javed as Zonal Sales Manager and Mr. Ashok Chauhan as Regional Sales Manager. These appointments aim to strengthen the sales and export structure to support business expansion and international growth. No financial considerations were disclosed in the announcement.
Shelter Pharma Limited informed the exchange that the Annual Secretarial Compliance Report under Regulation 24A is not applicable to the company. As an entity listed on the BSE SME platform, it is exempt from certain SEBI LODR provisions. This is a routine regulatory clarification for investors.
Shelter Pharma Ltd has initiated a structured hiring process for senior management roles, including Zonal, Area, and Export Heads. This expansion of the leadership team aligns with the company's strategic domestic growth plans and aims to enhance operational efficiency and long-term business performance.
Shelter Pharma Ltd has qualified the technical evaluation stage for a veterinary medicine supply tender from Verka Dairies. The company has been invited to a negotiation meeting to finalize contract terms. This development underscores the firm's growing credibility in the veterinary healthcare segment; final contract details will be disclosed in due course.